179results about How to "Promote apoptosis" patented technology

The invention relates to the technical field of application of bacteroides fragilis, and in particular relates to application of bacteroides fragilis in preparing a composition for preventing and treating colon cancer. Experiments show that bacteroides fragilis induces an organism to generate the anti-tumor effect in vivo, inhibit the tumor growth, accelerate tumor cell apoptosis and prolong the lifetime, so that bacteroides fragilis has a good effect in preventing and treating colon cancer. The invention explores novel use of bacteroides fragilis and develops a novel application field, thereby indicating that the bacteroides fragilis has good edible and officinal prospect. Bacteroides fragilis serving as probiotic can be used for preparing foods or medical compositions for preventing and treating colon cancer so as to provide a clinically health-care and preventing and treating food suitable for human to take.

Compounds and pharmaceutical compositions containing the same are provided, which are useful in therapeutic treatment or prevention of various diseases.

This invention pertains to certain carbamic acid compounds which inhibit HDAC (histone deacetylase) activity of the following formula:

wherein: Cy is independently a cyclyl group; Q¹ is independently a covalent bond or cyclyl leader group; the piperazin-1,4-diyl group is optionally substituted; J¹ is independently a covalent bond or —C(═;O)—; J² is independently —C(═O)— or —S(═O)₂—; Q₂ is independently an acid leader group; wherein: Cy is independently: C_3-20carbocyclyl, C_3-20heterocyclyl, or C_5-20aryl; and is optionally substituted; Q¹ is independently: a covalent bond; C_1-7alkylene; or C_1-7alkylene-X—C_1-7alkylene, —X—C^1-7alkylene, or C_1-7alkylene-X—, wherein X is —O— or —S—; and is optionally substituted; Q² is independently: C_4-8alkylene; and is optionally substituted; and has a backbone length of at least 4 atoms; or: Q² is independently: C_5-20arylene; C_5-20arylene-C_1-7alkylene; C_1-7alkylene-C_5-20arylene; or, C_1-7alkylene-C_5-20arylene-C_1-7alkylene; and is optionally substituted; and has a backbone length of at least 4 atoms; or a pharmaceutically acceptable salt, solvate, amide, ester, ether, chemically protected form, or prodrug thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, etc.

The present invention pertains to certain imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one compounds and analogs thereof, which, inter alia, inhibit RAF (e.g., B-RAF) activity, inhibit cell proliferation, treat cancer, etc., and more particularly to compounds of the formula (I): wherein: J is independently —O— or —NR^N1—; R^N1, if present, is independently —H or a substituent; R^N2 is independently —H or a substituent; Y is independently —CH═ or —N═; Q is independently —(CH₂)_j-M-(CH₂)_k— wherein: j is independently 0, 1 or 2; k is independently 0, 1, or 2; j+k is 0, 1, or 2; M is independently —O—, —S—, —NH—, —NMe—, or —CH₂—; each of R^P1, R^P2, R^P3, and R^P4 is independently —H or a substituent; and additionally R^P1 and R^P2 taken together may be —CH═CH—CH═CH—; L is independently: a linker group formed by a chain of 2, 3, or 4 linker moieties; each linker moiety is independently —CH₂—, —NR^N—, —C(═X)—, or —S(═O)₂—; exactly one linker moiety is —NR^N—, or: exactly two linker moieties are —NR^N—; exactly one linker moiety is —C(═X)—, and no linker moiety is —S(═O)₂—; or: exactly one linker moiety is —S(═O)₂—, and no linker moiety is —C(═X)—; no two adjacent linker moieties are —NR^N—; X is independently ═O or ═S; each R^N is independently —H or a substituent; A is independently: C_6-14carboaryl, C_5-14heteroaryl, C_3-12carbocyclic, C_3-12heterocyclic; and is independently unsubstituted or substituted; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, N-oxides, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit RAF (e.g., B-RAF) activity, to inhibit receptor tyrosine kinase (RTK) activity, to inhibit cell proliferation, and in the treatment of diseases and conditions that are ameliorated by the inhibition of RAF, RTK, etc., proliferative conditions such as cancer (e.g., colorectal cancer, melanoma), etc.

The present invention provides a single-stranded circular RNA and DNA, and a preparation method and application thereof, the single-stranded circular RNA and DNA can adsorb a single-stranded circularRNA or a single-stranded circular DNA of miRNA, thereby overcoming the disadvantage that a traditional single-stranded RNA is easily degraded and has low efficiency, and can release tumor suppressor gene ''co-silencing'' caused by the miRNA. The single-stranded circular RNA or DNA prepared by the method can specifically adsorb the target miRNA so as to inhibit the proliferation, migration and invasion of tumor cells and promote the apoptosis of the tumor cells, can regulate the proportion of immune cells, has good anti-tumor and immune regulation effects, and is expected to be developed as a therapeutic drug for tumors or immune diseases.

Methods and small molecule compounds for inhibition of cancer cell proliferation are provided. One example of a class of compounds that may be used is represented by the compound of Formula I or a pharmaceutically acceptable salt, N-oxide or solvate thereof, wherein A, B, D, E, F, G, I, J, R, R₁, R₂, R_2′, R₃, R₄, R₅, R₆, R₇, R₈, R₉ are as described herein.

Provided is a use of an miRNA of an Epstein-Barr virus (EBV), more specifically, EBV miR-BART4-5p, miR-BART4-3p, miR-BART1-5p, miR-BART15-3p, miR-BART5-5p, miR-BART5-3p, miR-BART16-5p, miR-BART16-3p, miR-BART17-3p, miR-BART21-3p, miR-BART18-5p, miR-BART7-5p, miR-BART9-5p, miR-BART22-5p, miR-BART20-3p, miR-BART13-5p, miR-BART13-3p, miR-BART2-3p, and mimics thereof for promoting apoptosis or inhibiting cell growth.

This invention discloses a quasi-Wicker yeast variety Wickerhamiella domercqiae var. sophorolipid. This strain is conserved in general microbe center in China microbe bacterial conservention and management committee (institute of microbe of Chinese Academy of Sciences, Beijing, China), and its preservation number is CGMCC No. 1576. This invention also discloses the appliance of the quasi-Wicker yeast variety in preparing sophorosid biosurfactant that can supress neoplasms outside of body. The sophorosid is prepared through following steps: (1) chamfer culture(2)seed culture(3) enlargement culture(4) fermentate collection(5)production separation, and others. This method has many advantanges, for example, it is easy to operate; the output of sophorosid is high; the generated sophorosid has high restraining rate to tumor cell...so it has very broad application prospect in drug field.

The invention belongs to the technical field of tea production, and particularly relates to a Tetrastigma hemsleyanum Duels et Gilg tea with high contents of Tetrastigma hemsleyanum Duels et Gilg flavone, polysaccharide and kaempferol, and a manufacturing method of the Tetrastigma hemsleyanum Duels et Gilg tea. The method comprises the following steps: (1), spreading fresh Tetrastigma hemsleyanumDuels et Gilg leaves for 10-20 minutes; (2), fixation: deactivating enzymes of the Tetrastigma hemsleyanum Duels et Gilg leaves by adopting a microwave tea fixation drier; (3), flat pressing for shaping: uniformly spreading the Tetrastigma hemsleyanum Duels et Gilg leaves subjected to fixation on a bamboo skin board, and pressing another bamboo skin board on the leaves to enable the cooled Tetrastigma hemsleyanum Duels et Gilg leaves to be shaped; and (4), drying: drying the semi-finished products processed in the step (2) by a microwave tea machine. The Tetrastigma hemsleyanum Duels et Gilg tea is natural green, is bright green in color and light green in grounds, does not contain caffeine, is rich in Tetrastigma hemsleyanum Duels et Gilg flavone, polysaccharide, kaempferol and other ingratiates, can effectively inhibit cancer cell proliferation, promotes cancer cell poptosis, has no toxic or side effects and is easy to absorb and beneficial to health. The Tetrastigma hemsleyanum Duels et Gilg leaves are tender, have less fibers, and can be eaten after being brewed.

The invention discloses a nucleotide sequence and an amino acid sequence of a human derived membrane-stabilization mutant gene CD40L-M, and a plasmid carrier pdsAAV-CB-CD40L-M. The invention further discloses a recombinant adeno-associated virus scAAV2/5-Y719F-CD40L-M using CD40L-M as a target gene and highly-efficiently transducing lung cancer cells, a preparation method thereof, and an application thereof in preparing anti-cancer drugs. In vitro and in vivo tests of transduction of the CD40L-M gene into the lung cancer cells show that generation of the sCD40L is substantially reduced, a traditional AAV transduction efficiency is improved by using the recombinant adeno-associated virus scAAV2/5-Y719F-CD40L-M, the lung cancer cells can be highly-efficiently transduced, and the CD40L-M gene induces retardance of cell cycles, promotes cell apoptosis, induces immunization activation, inhibits growth of lung cancer in the body and reduces side effects such as liver and kidney damage.

The invention relates to the structure of radioactive micro balls and a preparation method. At least one micro ball having isotopes which can radiate beta or gamma-ray is added in a biocompatible substance; and the biocompatible substance represents biological materials and chemical materials which can be used for the clinical cure: biologic glass, biologic ceramics, biologic resin and liposome, etc. The preparation method comprises the steps: 1. activation method: putting phosphorus or yttrium-containing into an irradiation container of an atom reacting device, and irradiating the micro balls with neutron, so that the phosphorus or the yttrium is activated to be radioactive phosphorus (32P) or radioactive yttrium (90Y); and 2. mixing method: mixing isotope (such as 125I and 103Pd) which has radiate beta or gamma- ray with entitative or hollow micro balls, carrying the isotopes into human bodies by taking the micro balls as the carrier of the isotope for the radiotherapy of tumor. The radioactive micro balls have the volume which is in the range of nanometer and micrometer, and can release beta or gamma ray; and the isotope is one or several, has short radiation range, reduces the side effects of the radiotherapy of the tumor, and can be induced into the human bodies by means of local intervention or surgery through blood vessels.

The invention relates to the field of microorganisms, and discloses lactobacillus fermentum with a weight reducing function and an application of the lactobacillus fermentum. The lactobacillus fermentum is named as WHH3906, is separated from butter collected in Tibet Autonomous Region in China, is preserved in China General Microbiological Culture Collection Center on March 13, 2020, has a preservation number of CGMCC NO.19472, and is classified and named as lactobacillus fermentum. The lactobacillus fermentum strain can effectively reduce serum leptin level to recover leptin sensitivity of anorganism, effectively prevent and treat obesity, relieve non-alcoholic fatty liver and relieve chronic inflammation. After being compounded with lactobacillus plantarum 1701, the lactobacillus fermentum can synergistically relieve chronic inflammation.

The invention provides an active bactericidal medicine. The active bactericidal medicine is used for substituting general spray fungicide such as peroxyacetic acid, and can be used as medical bactericidal medicines at the same time. The invention further provides a preparation method and special equipment of the active bactericidal medicine. The active bactericidal medicine is safe and not-toxic, the continuous sterilizing can be realized under presence of people, and the stability is good.

The invention relates to a method of efficiently separating embryonic stem cells of poultry. The method comprises the steps: 1) taking out an embryonic disc from a hatching egg; 2) digesting and cleaning the embryonic disc and removing yolk of the embryonic disc; 3) conducting primary culture to the cells of the digested embryonic disc; and 4) enriching and purifying the embryonic stem cells from the cells of the primarily cultured embryonic disc. The method is simple and easy, accurate and effective, high in repeatability and low in cost, equipment or reagent in the whole separation and culture system can be self-made or commercialized, a feeding layer is not prepared, enzymatic digestion and related processing are not needed, blood serum is not required, and about 20 thousand purified embryonic stem cells can be separated and cultured from one hatching egg, and can be used for in vitro transfection to conduct gene modification or apparent modification, thereby compacting the technological base for the transgenic poultry, installing a boost accelerator for development of a bioreactor and the realization of huge commercialization value, and having great scientific research values and popularization significance.

The invention discloses application of a substance capable of reducing expression of a zinc finger protein CTCF to preparation of drugs for treating leukemia. In particular, the substance reducing expression of the zinc finger protein CTCF can be short hairpin RNA (shRNA) forming a stem-loop structure. The name of the shRNA is shRNA-3. One chain sequence of the stem in the stem-loop structure is SEQ ID No.1 and the other chain sequence of the stem in the stem-loop structure is SEQ ID No.2. The invention proves that the zinc finger protein CTCF is an anti-apoptosis factor and has the function of suppressing cell apoptosis in the ALL (acute lymphoblastic leukemia) cells. Apoptosis of tumor cells-leukemia cells can be promoted by interfering with expression of CTCF. The invention provides a new way for leukemia treatment. The zinc finger protein CTCF is expected to become a potential target for anti-leukemia treatment and has very extensive application prospect in the medical field.

The invention relates to a preparation method and biomedical application of a Fe3O4SiO2 (FITC) nano-vector integrated with magnetic resonance imaging, fluorescence imaging and targeting gene therapy. The nano-vector is prepared by virtue of the following steps: taking silicone having low toxicity and excellent biocompatibility as a raw material; firstly, synthesizing Fe3O4SiO2 nanoparticles doped with a fluorescent dye by use of an improved St.ber method, and linking polyethyleneimine (PEI) capable of improving the transfection efficiency with folic acid (FA) capable of targeting a folate receptor by virtue of an amidation reaction to form a PEI-FA polymer; further modifying the Fe3O4SiO2 (FITC) nanoparticles by use of the PEI-FA polymer, and adsorbing the shRNA of Notch-1 to form the compound nano-vector. The nano-vector has the functions of magnetic resonance imaging and fluorescence imaging, and further is capable of conveying a targeting gene to a tumor part to silence the expression of a target gene and inhibit the growth of the tumor.

The invention offers two sets of tumor-dissolving recombination adenovirus. One set is produced by rite-directed mutagenesis in virus E1A gene. The other set produced by replacing E1A promoter with tumor specificity promoter. The fiber end of parts of the recombination adenovirus is added RGD short peptide. And parts of are carried HSV₁-tkm. It is proved by experiment that the two sets of virus can strongly infect tumor cell, do a great deal replication and breeding, and finally dissolve cell. The released filial generation adenovirus can infect around tumor cell again. Thus dosage effect and against cancer capability of virus gene can be enlarged by breeding infecting cycle. The tow sets of tumor-dissolving recombination adenovirus appearances strong against cancer effect in animal subcutaneous, human liver and lung tumor model test.

The invention discloses a Chinese medicinal composition and a preparation method and application thereof. The Chinese medicinal composition is prepared from 20 to 40 percent of astragalus extract, 20 to 40 percent of asparagus root extract, 5 to 25 percent of finger citron extract and 15 to 35 percent of American ginseng in percentage by weight. Pharmacological experiments and clinical experiments show that the Chinese medicinal composition provided by the invention has the functions of strengthening body resistance and eliminating evil, nourishing yin and tonifying qi, clearing heat and releasing toxin, eliminating tuberculosis and dissipating stagnation, and mainly treats the symptoms of qi and yin deficiency, qi stagnation, blood stasis, phlegm coagulation, toxin aggregation and the like caused by malignant tumors; when the Chinese medicinal composition is used with radiation therapy and chemical therapy, the Chinese medicinal composition has the effects of increasing efficacy, reducing toxicity and inhibiting growth and transfer of the tumors, can reverse the medicament resistance of tumor cells and promote apoptosis of the tumor cells, and has not obvious toxic or side effect; and meanwhile, the preparation method for the Chinese medicinal composition has the advantages of quality stability and controllability, extraction of high active ingredient content and strong operability, and is suitable for industrialized mass production.

The invention discloses an application of curcumin in the preparation of a thyroid carcinoma therapeutic agent, and belongs to the technical field of curcumin pharmaceutical application. Curcumin can kill thyroid carcinoma cells specifically and has little influence on normal thyroid cells. Curcumin can promote the apoptosis of thyroid carcinoma cells, initiate the digestion of poly adenosine diphosphate-ribose polymerase (PARP), and significantly inhibit the expression of anti-apoptotic protein Bcl-2; meanwhile, curcumin can also inhibit the secretion of thyroid carcinoma cell matrix metalloproteinase-9 and the adhesion to extracellular matrix. Above results show that curcumin has good intervention effect on various links of proliferation, migration, and adhesion of thyroid carcinoma cells, and is applicable to the preparation of medicaments for treating thyroid carcinoma.

The invention relates to a siRNA molecular composition and application thereof in treatment on hypertrophic scars and keloids. The siRNA molecular composition contains siRNA molecules with the sequence of 5'-CCCAAGGGCUACCAUGCCAACUUCU-3' and siRNA molecules with the sequence of 5'-GGUCUGGUGCCUGGUCUGAUGAUGU-3'. The siRNA molecular composition is proved to be capable of promoting in-vitro fibroblast apoptosis of the hypertrophic scars and keloids and have a good treatment effect on the hypertrophic scars in an animal model.

The invention discloses a pyrazolo[3,4-d]pyrimidine derivative that is represented as the formula (I), which has significant growth inhibiting effect, apoptosis promoting effect and cell proliferation alleviating effect on tumor cells, can be used for preventing and/or treating tumor related diseases, and has wide application prospect.

The invention relates to a preparation method for albumin nano-particles and the albumin nano-particles prepared by the method and a pharmaceutical use of the albumin nano-particles. The preparation method comprises the following steps: 1) dissolving the albumin in urea solution, uniformly mixing, adding sodium borohydride solution to obtain the urea solution of albuminate; and 2) adding absolute ethyl alcohol or other organic solvents to the urea solution of the albuminate, and adding purified water, namely forming the albumin nano-particles. In addition, the invention further relates to the albumin nano-particles prepared by the method and the pharmaceutical use of the albumin nano-particles.

This invention pertains to certain carbamic acid compounds of the formula (I), which inhibit HDAC (histone deacetylase) activity: wherein: J is a linking functional group and is independently: —O—C(═O)— or —C(═O)—O— or —C(═O)—; Cy is a cyclyl group and is independently: C_3-20carbocyclyl, C_3-20heterocyclyl, or C_5-20aryl; and is optionally substituted; Q¹ is a cyclyl leader group, and is independently a divalent bidentate group obtained by removing two hydrogen atoms from a ring carbon atom of a saturated monocyclic hydrocarbon having from 4 to 7 ring atoms, or by removing two hydrogen atoms from a ring carbon atom of saturated monocyclic heterocyclic compound having from 4 to 7 ring atoms including 1 nitrogen ring atom or 1 oxygen ring atom; and is optionally substituted; Q² is an acid leader group, and is independently: C_1-8alkylene; and is optionally substituted; or: Q² is an acid leader group, and is independently: C_5-20arylene; C_5-20arylene-C_1-7alkylene; C_1-7alkylene-C_5-20arylene; or C_1-7alkylene-C_5-20arylene-C_1-7alkylene; and is optionally substituted; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, etc.

The invention discloses a nucleic acid aptamer modified molybdenum disulfide nanosheet photothermal agent with targeted identification. A molybdenum disulfide nanosheet photothermal therapy system having the targeting ability is constructed in the invention, wherein the diameter range of a functionalized molybdenum disulfide nanosheet MoS2-BSA-Apt is 80-120 nm; the size of MoS2 in the functionalized molybdenum disulfide nanosheet is 10 nm; the functionalized molybdenum disulfide nanosheet has excellent photothermal effect under irradiation of infrared light; and the functionalized molybdenum disulfide nanosheet has the capability of specifically identifying tumour cells, can be enriched around the tumour cells, and can be moved into target cells. The nucleic acid aptamer modified molybdenum disulfide nanosheet photothermal agent in the invention is an excellent photothermal therapy material, which has excellent biocompatibility and stability, and is high in photothermal conversion efficiency, simple to synthesize, low in cost and toxicity and high in metabolic rate, has the targeting ability, and can be used for treating tumours precisely and effectively.

The invention relates to a traditional Chinese medicine for treating the tumor of the digestive tract, strengthening the body resistance and removing summer-heat, which is characterized by being mainly prepared from several following bulk drugs according to mixture ratio by weight: 15 to 45 parts of astragalus root, 15 to 45 parts of glossy privet fruit, 15 to 45 parts of self-heal and 15 to 45 parts of oldenlandia diffusa. By applying the invention to the clinical auxiliary treatment of the tumor of the digestive tract, the invention has the functions of improving the immunological function, lowering the relapse rate, enhancing the accumulative survival rate and the like.

The invention belongs to the field of molecular genetics biology and discloses application of a Wnt/beta-catenin signal channel inhibitor to the preparation of a medicament for promoting apoptosis. The Wnt/beta-catenin signal channel inhibitor is preferably siRNA (small interfering Ribonucleic Acid) of beta-catenin. Chemical synthesis beta-catenin-siRNA is designed specific to beta-catenin genes,and granular cells are transferred with a lipoplast, so that the beta-catenin genes in pig ovary granular cells are decreased. A result shows that apoptotic cells in an experimental group are remarkably increased from 8.80 percent to 15.85 percent in comparison to a blank group after beta-catenin expression is inhibited, the difference is remarkable, and the beta-catenin-siRNA can promote the apoptosis of granular cells.

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain pyridyl-amino-pyrazine carbonitrile compounds that, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or thymidylate synthase (TS) inhibitor; (d) a microtubule targeted agent; and (e) ionising radiation.

The invention discloses deoxyribozyme for promoting tumor cell apoptosis, which comprises a deoxynucleotide sequence 5'-GGCTAGCTACAACGA-3', a first binding sequence and a second binding sequence, wherein the deoxynucleotide sequence 5'-GGCTAGCTACAACGA-3' has catalyzing function; and the first binding sequence and the second binding sequence are respectively connected with the 5' end and the 3'end of the catalyzing function sequence, respectively comprise 7 to 12 nucleotides and are complemented to the 3'end and 5' end sequences of an R*Y cutting site of an apoptosis inhibiting gene mRNA or pre-mRNA in a bc1-2family. The deoxyribozyme of the invention reduces the expression of the apoptosis inhibiting gene by specifically recognizing and cutting the apoptosis inhibiting gene mRNA or pre-mRNA, thereby promoting the tumor cell apoptosis and inhibiting the growth of tumors.

The invention discloses a novel anti-tumor amiRNA (artificial micro Ribonucleic Acid) sequence, which comprises any one or more than one of the following sequences: amiRNA-hTERT (human Telomerase Reverse Transcriptase) 1: positive-sense strand 5'-TGACCAAATGTGCCCTGTA-3'; anti-sense strand 5'-TACAGGGCACACCTTTGGTCA-3'; amiRNA-hTERT 2: positive-sense strand 5'-CAGAGCCACTCACCTTCAA-3'; anti-sense strand 5'-TTGAAGGTGAGACTGGCTCTG-3'; amiRNA-hTERT 3: positive-sense strand 5'-CAGAGCCAGTCTCACCTTCAA-3'; and anti-sense strand 5'-TTGAAGGTGAGACTGGCTCTG-3'. According to the novel anti-tumor amiRNA sequence, growth, proliferation and migration of tumor can be inhibited, so that tumor cells enter an aging state to promote the apoptosis of the tumor cells.

The invention provides small molecule mimics of the Smac peptide that are dimer- or dimer-like compounds having two amide-containing domains connected by a linker. These compounds are useful to promote apoptosis. The invention includes pharmaceutical compositions comprising such compounds and methods to use them to treat conditions including cancer and autoimmune disorders.